Method for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated

• US 8,165,681 B2
• Filed: 10/31/2007
• Issued: 04/24/2012
• Est. Priority Date: 05/17/2001
• Status: Expired due to Fees

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: King, Gary W.
• Primary Examiner(s): Schaetzle, Kennedy
• Application Number:
  US11/930,725
• Publication Number:
  US 20080058888A1
• Time in Patent Office: 1,637 Days
• Field of Search: None
• US Class Current: 607/40
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/36071 Pain
• CPC Class Codes: A61N 1/39624 Pain reduction therapy

Abstract

A desired effect is produced by therapeutically activating tissue at a first site within a patient'"'"'s body and a corresponding undesired side effect is reduced by blocking activation of tissue or conduction of action potentials at a second site within the patient'"'"'s body by applying high frequency stimulation and/or direct current pulses at or near the second site. Time-varying DC pulses may be used before or after a high frequency blocking signal. The high frequency stimulation may begin before and continue during the therapeutic activation. The high frequency stimulation may begin with a relatively low amplitude, and the amplitude may be gradually increased. The desired effect may be promotion of micturition or defecation and the undesired side effect may be sphincter contraction.

Claims

1. A method of blocking undesirable side effect activation of electrically excitable tissue, the method comprising the steps of:

therapeutically activating tissue at a first predetermined site within a patient'"'"'s body; and

blocking activation of tissue or conduction of action potentials at a second predetermined site within the patient'"'"'s body by applying high frequency stimulation or one or more direct current pulses or both high frequency stimulation and one or more direct current pulses at or near the second site, wherein the undesired effect is muscle contraction;

the desired effect is peristalsis of the patient'"'"'s ureter; and

the undesired side effect is closure of the patient'"'"'s anti-reflux valves near the patient'"'"'s bladder trigone.

2. The method of claim 1, wherein:

the first site is selected from the group consisting of the patient'"'"'s;

renal pelvis and a portion of the patient'"'"'s ureter.

3. The method of claim 1, wherein:

the second site is the base of the patient'"'"'s bladder near an entrance of the ureter, hypogastric plexus, and pelvic plexus.

4. A method of blocking undesirable side effect activation of electrically excitable tissue, wherein such undesirable side effect activation includes muscle contraction, the method comprising the steps of:

therapeutically activating tissue at a first predetermined site within a patient'"'"'s body by applying low frequency stimulation at or near the first predetermined site; and

blocking activation of tissue or conduction of action potentials at a second predetermined site within the patient'"'"'s body by applying high frequency stimulation or one or more direct current pulses or both high frequency stimulation and one or more direct current pulses at or near the second site such that the high frequency stimulation and/or the direct current pulses prevent the low frequency stimulation applied at the first site from activating the electrically excitable tissue, or causing conduction of action potentials, at the second site, wherein;

the desired effect is peristalsis of the patient'"'"'s ureter and the first site is selected from the group consisting of the patient'"'"'s;

renal pelvis and a portion of the patient'"'"'s ureter; and

the undesired side effect is closure of the patient'"'"'s anti-reflux valves near the patient'"'"'s bladder trigone and the second site is the base of the patient'"'"'s bladder near an entrance of the ureter, hypogastric plexus, and pelvic plexus.

5. The method of claim 4, wherein the high frequency stimulation or the direct current pulses or both the high frequency stimulation and the direct current pulses begin before and continue during the therapeutic activation.

6. The method of claim 4, wherein the high frequency stimulation or the direct current pulses or both the high frequency stimulation and the direct current pulses begin with a relatively low amplitude and the amplitude is gradually increased.

7. The method of claim 4, wherein the high frequency stimulation or the direct current pulses or both the high frequency stimulation and the direct current pulses are terminated by gradually reducing the amplitude of the high frequency stimulation or the direct current pulses or both the high frequency stimulation and the direct current pulses.

8. The method of claim 4, further comprising the steps of:

sensing a state of the tissue at the second site or at a site that is remote from both the first site and the second site; and

in response to the sensing step, adjusting at least one parameter of the high frequency stimulation or the direct current pulses or both the high frequency stimulation and the direct current pulses, the parameter being selected from the group consisting of;

pulse amplitude, pulse width, pulse frequency, pulse duty cycle, pulse polarity, and pulse waveform.

9. The method of claim 8, further comprising:

sensing a state of the tissue at the second site or at a site remote from both the first site and the second site; and

in response to an indication from the sensor that tissue at the second site is activated, applying the high frequency stimulation or the direct current pulses or both the high frequency stimulation and the direct current pulses to the second site.